Novartis receives complete response letter from U.S. FDA for inclisiran

18 December 2020 - The U.S. FDA has not raised any concerns related to the efficacy or safety of inclisiran. The ...

Read more →

enGene receives fast track designation for EG-70 for the treatment of non-muscle invasive bladder cancer

3 December 2020 - enGene announced today that the U.S. FDA has granted fast track designation to enGene for EG-70, the ...

Read more →

Taysha Gene Therapies receives rare paediatric disease designation and orphan drug designation for TSHA-104 to treat SURF1 associated Leigh syndrome

27 October 2020 - Taysha anticipated to submit Investigational new drug application for TSHA-104 to FDA in 2021. ...

Read more →

Taysha Gene Therapies receives rare paediatric disease designation and orphan drug designation for TSHA-102 as a treatment for Rett syndrome

14 October 2020 - Program leverages novel miRARE platform technology used to control transgene expression on a cellular basis. ...

Read more →

Axovant Gene Therapies receives rare paediatric disease designation for AXO-AAV-GM1 for GM1 gangliosidosis

9 October 2020 - Company on-track to report data from on-going Phase 1/2 clinical study in Q4 2020. ...

Read more →

BioMarin receives FDA fast track designation for investigational gene therapy, BMN 307

2 October 2020 - Second investigational gene therapy in clinic, potential third therapy in PKU franchise. ...

Read more →

Pfizer receives FDA fast track designation for Duchenne muscular dystrophy investigational gene therapy

1 October 2020 - Pfizer today announced that its investigational gene therapy candidate (PF-06939926) being developed to treat Duchenne muscular dystrophy ...

Read more →

FDA grants Spirovant Sciences orphan drug and rare paediatric disease designations for SPIRO-2101 for treatment of cystic fibrosis

24 September 2020 - Spirovant Sciences today announced that the U.S. FDA has granted orphan drug and rare paediatric disease ...

Read more →

Gyroscope Therapeutics granted FDA fast track designation for GT005, an investigational gene therapy for dry age-related macular degeneration

22 September 2020 - Gyroscope Therapeutics today announced that the U.S. FDA has granted fast track designation to GT005 for the ...

Read more →

Taysha Gene Therapies receives orphan drug designation and rare paediatric disease designation for TSHA-101 for GM2 gangliosidosis

27 August 2020 - TSHA-101 anticipated to advance into the clinic by the end of 2020. ...

Read more →

BioMarin receives complete response letter from FDA for valoctocogene roxaparvovec gene therapy for severe haemophilia A

19 August 2020 - FDA introduces new recommendation for 2 year annualised bleeding rate as primary outcome for on-going Phase 3 ...

Read more →

4D Molecular Therapeutics receives FDA fast track designation for 4D-310 gene therapy for treatment of Fabry disease

13 August 2020 - 4D Molecular Therapeutics announced that the U.S. FDA has granted fast track designation to 4D-310 for ...

Read more →

Sarepta Therapeutics receives fast track designation for SRP-9001 micro-dystrophin gene therapy for the treatment of Duchenne muscular dystrophy

24 July 2020 - Sarepta Therapeutics today announced that the U.S. FDA has granted fast track designation to SRP-9001 (AAVrh74.MHCK7.micro-dystrophin).  ...

Read more →

Gene therapy shows promise for haemophilia, but could be most expensive U.S. drug ever

20 June 2020 - Jack Grehan, who was born with hemophilia, used to inject himself every couple of days with ...

Read more →

Cell and gene therapies: FDA official on COVID-19 impact

10 June 2020 - Speaking at a session on cell and gene therapies at BIO Digital on Monday, a top US ...

Read more →